{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative.","groups":[{"description":"See detailed description or participant flow.","id":"OG000","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who reported a Complete Response (CR) during treatment and were analyzed for the presence of circulating leukemia cells.","reportingStatus":"POSTED","timeFrame":"9 years 4 months","title":"Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)","type":"SECONDARY","unitOfMeasure":"Participants"}